

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Problem Image Mailbox.**

What is claimed is:

1. A method of decreasing the motility of an $\alpha v \beta 3$ integrin expressing cell comprising cross-linking at least two $\alpha v \beta 3$ integrins on said integrin expressing cells thereby inhibiting the motility of said cells.
2. The method of claim 1, wherein the integrins are cross linked by a homodimeric disintegrin.
3. The method of claim 2, wherein the homodimeric disintegrin is contortrostatin.
4. The method of claim 1, wherein the crosslinking disrupts FAK signaling.
5. The method of claim 1, wherein the crosslinking activates tyrosine phosphorylation of FAK
6. The method of claim 1, wherein the crosslinking activates tyrosine phosphorylation of CAS.
7. The method of claim 1, wherein the crosslinking induces an alteration in cell morphology.
8. The method of claim 7, wherein the alteration changes cytoskeletal or focal adhesion structures.
9. The method of claim wherein the $\alpha v \beta 3$ integrin expressing cell is a tumor cell.
10. A method of inhibiting the adhesion of integrin expressing cells to vitronectin comprising exposing said cells to contortrostatin so that contortrostatin binds to the integrin.
11. The method of claim 10, wherein said integrin is $\alpha v \beta 3$ or $\alpha v \beta 5$.

12. A homodimeric disintegrin comprising an amino acid sequence which is at least 90% percent identical to amino acid numbers 419 to 483 of SEQ ID NO: 2, wherein said contortrostatin amino acid sequence (i) binds to integrin $\alpha v \beta 5$ and (ii) induces $\alpha v \beta 3$ -mediated tyrosine phosphorylation of CAS and FAK in tumor cells.

13. The homodimeric disintegrin of claim 12 having an amino acid sequence selected from the group consisting of :

- (a) amino acid numbers 419 to 483 of SEQ ID NO: 2;
- (b) an amino acid sequence at least 95% identical to (a) as determined by FASTA or BLAST using default opening and gap penalties and a default scoring matrix.

14. A pharmaceutically acceptable composition comprising a pharmaceutically acceptable carrier and a homodimeric disintegrin according to claim 12.